Adenosine 5′-triphosphate (ATP)

Angiosarcoma (AS)

Base medium (BM)

BRM-associated factor (BAF)

BRCA1-associated RING domain 1 (BARD1)

BRM-associated factor (BAF)

Chondrosarcoma (CS)

Chordoma (CD)

Ewing sarcoma (ES)

Extrauterine soft tissue leiomyosarcoma (ESTL)

Extraskeletal myxoid chondrosarcoma (EMC)

Epithelioid sarcoma (ES)

Dermatofibrosarcoma protuberans (DFSP)

Gastrointestinal stromal tumor (GST)

Giant osteosarcoma (GOS)

Growth media (GM)

Hemangiopericytoma (HP)

Hyaluronic acid (HA)

Immunohistochemistry (IHC)

Immune-enhanced patient-derived sarcoma organoids (iPDSO)

Leiomyosarcoma (LMS)

Liposarcoma (LS)

Malignant fibrous histiocytoma (MFH)

malignant giant-cell tumor (MGT)

Malignant peripheral nerve sheath tumor (MPNST)

malignant schwannoma (MS)

Metalloproteinases (MMP9)

Myxofibrosarcoma (MFS)

Not applicable (N/A)

Osteosarcoma (OS)

Patient-derived organoids (PDO)

Patient-derived sarcoma organoids (PDSO)

Pleiomorphic abdominal sarcoma (PAS)

Poly [ADP-ribose] polymerase 1 (PARP1)

Programmed cell death protein 1 (PD1)

Rhabdomyosarcoma (RMS)

Short tandem repeat (STR)

SRY-box transcription factor 9 (Sox9)

Synovial sarcoma (SS)

Three-dimensional (3-D)

Tumor mutational burden (TMB)

Two-dimensional (2-D)

Undifferentiated pleomorphic sarcoma (UPS)

Vimentin (VIM)